Barrowcliffe Susan E. 4
4 · Aimmune Therapeutics, Inc. · Filed Sep 27, 2017
Insider Transaction Report
Form 4
Barrowcliffe Susan E.
General Manager, Europe
Transactions
- Exercise/Conversion
Common Stock, $0.0001 par value
2017-09-25$3.02/sh+20,000$60,440→ 20,000 total - Sale
Common Stock, $0.0001 par value
2017-09-25$25.00/sh−20,000$500,000→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2017-09-25−20,000→ 168,400 totalExercise: $3.02Exp: 2025-05-13→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- [F2]The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.